Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06663072 · ClinicalTrials.gov registry record · Phase 1
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
A Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06663072: Recruiting Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor, sponsored by University of Chicago.
NCT06663072 is a Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06663072, a Phase 1 study of Metastatic Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Primary Outcome
The rates of tumor response categories (CR, PR, SD, PD, Not Evaluated, Too Early) will be summarized and compared to historical control of response to PRRT treatment.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG 177Lu-DOTATATE
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT06663072 shows while recruiting
NCT06663072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Metastatic Pancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT06663072 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06663072 about?
NCT06663072 is a clinical study titled "Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors". This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
What is the current status of trial NCT06663072?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-12-13. Estimated completion is 2026-11.
What conditions does trial NCT06663072 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT06663072?
The interventions under investigation include: Fulvestrant (DRUG), 177Lu-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT06663072?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06663072 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06663072's enrollment target sits among peer trials
25 1496th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 1
-
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI